Orca Bio secured $250 million to support the commercial launch of its allogeneic T‑cell therapy, a financing aimed at building manufacturing, commercialization and market access capabilities for post‑stem‑cell‑transplant complications. City of Hope and Cellares signed an agreement to evaluate automated manufacturing and QC for a glioblastoma CAR‑T program. The collaboration targets reproducible, high‑throughput production for solid‑tumor CAR‑T, signaling increased emphasis on automation to lower failure rates and scale supply for cell therapies beyond hematologic indications.